Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

6Total
P 1 (3)
P 3 (2)
P 4 (1)

Trial Status

Recruiting3
Not Yet Recruiting1
Unknown1
Active Not Recruiting1

Clinical Trials (6)

Showing 6 of 6 trials
NCT07384715Phase 1Recruiting

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

NCT04068597Phase 1Recruiting

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT06641414Phase 3RecruitingPrimary

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

NCT05320809Phase 1Active Not Recruiting

Study of 3D189 in Patients With Hematologic Malignancies

NCT06927232Phase 3Not Yet RecruitingPrimary

AZA+Lus VS AZA Monotherapy in HR-MDS

NCT01806116Phase 4UnknownPrimary

Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation

Showing all 6 trials

Research Network

Activity Timeline